A Splicing Factor Called SRSF1 Helps Ischemic Tissue Grow New Blood Vessels
Mouse and cell studies show endothelial SRSF1 drives blood vessel growth after ischemia through an ATF3-KLF2-S1PR1 pathway, hinting at new options for artery disease.
Summary
Peripheral artery disease restricts blood flow to the limbs, and no drug effectively restores it. Researchers found that a splicing protein, SRSF1, builds up in the endothelial cells lining blood vessels when muscle is starved of oxygen. In mice with hindlimb ischemia, removing SRSF1 from endothelial cells slowed blood flow recovery and vessel formation, while boosting SRSF1 improved both. In human endothelial cells, SRSF1 increased tube formation, sprouting, and migration. Mechanistically, SRSF1 shifts splicing of ATF3 toward the full-length form, which represses KLF2 and dampens S1PR1 signaling, favoring angiogenesis. The prostaglandin E1 analog alprostadil also activated this SRSF1 signaling and improved angiogenesis in cells and mice. The findings point to endothelial SRSF1 as a possible therapeutic target, but they come from preclinical models and need testing in humans.
Detailed Summary
Peripheral artery disease (PAD) occurs when narrowed arteries starve limbs of blood, and it has no effective drug therapy. Stimulating new vessel growth (angiogenesis) to restore perfusion is a promising strategy, yet the molecular controls of ischemia-driven angiogenesis in endothelial cells are poorly understood.
The team used proteomic analysis of ischemic mouse muscle and found that the splicing factor SRSF1 accumulated in endothelial cells and responded to low oxygen. They then used loss- and gain-of-function approaches in a mouse hindlimb ischemia model and in cultured human endothelial cells. Transcriptome analysis, eCLIP sequencing, RNA pull-down, and ChIP-qPCR were used to map the mechanism.
Mice lacking endothelial SRSF1 recovered blood flow poorly and formed fewer vessels after ischemia. Overexpressing SRSF1 improved blood flow recovery and angiogenesis. In human endothelial cells, SRSF1 increased tube formation, sprouting, and migration, while knockdown reduced them. SRSF1 bound ATF3 pre-mRNA and favored the full-length transcript over the truncated ATF3Δzip2 variant. Full-length ATF3 bound the KLF2 promoter, suppressing KLF2 and downstream S1PR1 signaling, which promoted angiogenesis. Alprostadil, a prostaglandin E1 analog, activated SRSF1 signaling and improved angiogenesis in vitro and in vivo.
The work identifies SRSF1 and the ATF3-KLF2-S1PR1 axis as potential targets for ischemic vascular disease, and it suggests an existing drug may act partly through this pathway.
Caveats: this summary is based on the abstract only. The evidence is preclinical, drawn from mouse models and cultured cells, and has not been tested in patients. Safety of manipulating a broadly acting splicing factor, including risks of excessive or tumor-promoting angiogenesis, is not addressed in the abstract.
Key Findings
- SRSF1 accumulates in endothelial cells of ischemic mouse muscle and responds to hypoxia.
- Endothelial SRSF1 deficiency impaired blood flow recovery and vessel formation after hindlimb ischemia in mice.
- SRSF1 overexpression improved blood flow recovery and angiogenesis, and boosted tube formation, sprouting, and migration in human endothelial cells.
- SRSF1 favors full-length ATF3 over ATF3Δzip2, which represses KLF2 and S1PR1 signaling to promote angiogenesis.
- Alprostadil activated SRSF1 signaling and improved endothelial angiogenesis in cells and mice.
Methodology
Researchers combined proteomics of ischemic muscle with endothelial-specific loss- and gain-of-function approaches in a mouse hindlimb ischemia model and in cultured human endothelial cells. Mechanisms were dissected using transcriptome analysis, eCLIP sequencing, RNA pull-down, and ChIP-qPCR.
Study Limitations
Evidence is preclinical, from mouse models and cultured cells, and only the abstract was available for this summary. Sample sizes, durability of effects, and safety concerns such as off-target splicing changes or pathologic angiogenesis are not described. Whether the pathway operates in human PAD patients remains untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
